Rashmi Kothary

Dr. Rashmi Kothary

Deputy Scientific Director and Senior Scientist, Ottawa Hospital Research Institute

Professor, University of Ottawa

NMD4C Involvement: Pillar 1: Preclinical Science, Theme 5: Open Science

Email Rashmi


Dr. Kothary is the Deputy Scientific Director and Senior Scientist at the Ottawa Hospital Research Institute (OHRI). He has held the University Health Research Chair in Neuromuscular Disorders and is a Professor at the University of Ottawa. He has been instrumental in many leadership initiatives, including the creation, with Dr. Bernard Jasmin, of the University of Ottawa Centre for Neuromuscular Disease (CNMD). Today, this center represents the preeminent collection of neuromuscular disease researchers in Canada, bringing together more than 55 basic and clinical scientists working on a variety of disorders.

His current research focuses on investigating factors important for oligodendrocyte mediated myelination and remyelination of the CNS (in the context of Multiple Sclerosis) and understanding spinal muscular atrophy (SMA) pathogenesis to identify novel therapeutics for this devastating children’s disease. In this regard, his group is demonstrating that SMA is a multisystem disorder, and that it is critical to develop whole body therapies when treating patients.

He presently sits on the scientific advisory boards of SMA Beyond (which is based in Europe) and Cure SMA USA. Previously, he has served on the scientific advisory board for CIHR Institute of Musculoskeletal Health and Arthritis and Muscular Dystrophy Association USA, and currently is a reviewer for the CIHR, NIH, MDA and Shriners Hospitals for Children. 

Recent Publications

Kornfeld, SF, Cummings, SE, Yaworski, R, De Repentigny, Y, Gagnon, S, Zandee, S et al.. Loss of miR-145 promotes remyelination and functional recovery in a model of chronic central demyelination. Commun Biol. 2024.7 (1)813 PMID:38965401

Gigliotta, A, Mingardi, J, Cummings, S, Alikhani, V, Trontti, K, Barbon, A et al.. Genetic background modulates the effect of glucocorticoids on proliferation, differentiation and myelin formation of oligodendrocyte lineage cells. Eur J Neurosci. 2024.59 (9)2276-2292 PMID:38385867

Reilly, A, Yaworski, R, Beauvais, A, Schneider, BL, Kothary, R. Long term peripheral AAV9-SMN gene therapy promotes survival in a mouse model of spinal muscular atrophy. Hum Mol Genet. 2024.33 (6)510-519 PMID:38073249

Alves, CRR, Ha, LL, Yaworski, R, Sutton, ER, Lazzarotto, CR, Christie, KA et al.. Optimization of base editors for the functional correction of SMN2 as a treatment for spinal muscular atrophy. Nat Biomed Eng. 2024.8 (2)118-131 PMID:38057426

Benlefki, S, Younes, R, Challuau, D, Bernard-Marissal, N, Hilaire, C, Scamps, F et al.. Differential effect of Fas activation on spinal muscular atrophy motoneuron death and induction of axonal growth. Cell Mol Biol (Noisy-le-grand). 2023.69 (10)1-8 PMID:37953591

See more on PubMed